Biotech Values

[Bickema]

I don't have enough industry knowledge to weigh in but I do fancy your hypothesis and do think its quite reasonable.

If I remember correctly, didn't the FDA revise their botulinum toxin guidelines back in 2014 to encourage botox generics? I can't find the article

Anyway I find it encouraging that the new hires were willing to jump ship from very sucsessful, multibillion dollar companies that will surely be around for decades to come, to join Revance.

It also strengthens my perception that Dan Browne has no plans to buy time or coast off free shares and compensation. He is as serious as a heart attack at getting RT002 to market as soon as possible.

Question: How do these new hires affect your opinion on potential partnerships for RT002?